Allarity Therapeutics, Inc. (ALLR) is a Healthcare stock trading at $1.40 (as of 2026-08-21), with a market capitalization of $22.28M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Allarity Therapeutics develops oncology therapeutics and associated drug-specific companion diagnostics, using its drug response predictor technology to match treatments to drug-response patients; its pipeline includes clinical-stage candidates such as Stenoparib (Phase 2 for ovarian cancer) and LiPlaCis (Phase 2 clinical trials for).
The company’s future profitability depends on whether its drug-response predictor based companion diagnostic approach successfully translates into clinical efficacy for each oncology candidate, including Phase 2 programs.
Business quality (Weak): Good high-level business clarity from the description (therapeutics plus companion diagnostics), but limited investor view here because no official reportable segments or operating KPIs were provided, and there is no disclosed revenue history (latest quarter revenue is shown as 0.0B).
| Price | $1.40 |
| Market Cap | $22.28M |
| Price / Book | 6.30 |
| Price / Sales | 93.99 |
| FCF Yield | -72.9% |
| Revenue (TTM) | $320000.00 |
| Net Margin | -3509.7% |
| Revenue Growth (YoY) | -40.0% |
| EPS Growth (YoY) | -95.0% |
| FCF Growth (YoY) | -16.0% |
| Altman Z-Score | -10.04 (distress) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| Top Institutional Holder | VANGUARD GROUP INC ($266445.00) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Thomas H. Jensen |
| Employees | 6 |
| Country | US |
| IPO Date | 2021-12-21 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.